Summary of Research: Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trials (the ENHANCE Trials)

By afschroeder • March 25, 2026

Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Rickard K, O'Donovan K, Sciurba F. Summary of Research: Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trials (the ENHANCE Trials). Adv Ther. 2026 Mar 24. doi: 10.1007/s12325-026-03514-6. Epub ahead of print. PMID: 41874851.

Tags: COPD, Dual PDE3, ensifentrine, nebulized therapy, PDE4 Inhibitor, Publications, Pulmonary, Critical Care & Sleep Medicine

Mucus plugs in chronic obstructive pulmonary disease are heterogeneous in size and shape and occur in relatively large airways

Farooqui ON, Elicker BM, Henry TS, Hahn LD, Kallianos KG, Han MK, Barr RG, Smith BM, Comellas AP, Bon J, Hansel N, Wells JM, Paine[...]

Measures of Vascular Volume in the Lung: An Emerging Quantitative Tool for Clinical and Physiological Studies in Pulmonary Vascular Disease

Rahaghi FN. Measures of Vascular Volume in the Lung: An Emerging Quantitative Tool for Clinical and Physiological Studies in Pulmonary Vascular Disease. Am J Respir[...]

Genomic surveillance of human metapneumovirus in the United States, 2010-2025

Bendall EE, Fitzsimmons WJ, Valvano WD, Truscon R, Self WH, Halasa N, Chappell JD, Zhu Y, Safdar B, Ginde AA, Peltan ID, Gaglani M, Columbus[...]